2012598-34-2
2012598-34-2
Chemical Structure
Carprofen-13C,d3
- CAS No.: 2012598-34-2
- Formula:C1413CH9D3ClNO2
- Molecular Weight:277.73
IUPAC Name: 2-(6-chloro-9H-carbazol-2-yl)propanoic-3-13C-3,3,3-d3 acid
InChIKey: PUXBGTOOZJQSKH-KQORAOOSSA-N
SMILES: ClC1=CC=C2NC3=CC(C([13C]([2H])([2H])[2H])C(O)=O)=CC=C3C2=C1
Biological Activity: Carprofen-13C,d3 is the deuterium and 13C labeled Carprofen[1]. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively[2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Carprofen-13C,d3 | Carprofen-13C,d3 is the deuterium and 13C labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carprofen (Standard) | 99.84% | Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carprofen-d3 | Carprofen-d3 is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carprofen | 99.94% | Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Favia AD, et al. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem. 2012 Oct 25;55(20):8807-26. [Content Brief]
- [3]. Waldherr K, et al. In vitro cytoprotective effects of acetylsalicylic acid, carprofen, meloxicam, or robenacoxib against apoptosis induced by sodium nitroprusside in canine cruciate ligament cells. Am J Vet Res. 2012 Nov73(11):1752-8. [Content Brief]
- [4]. Sessions JK, et al. In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res. 2005 May66(5):812-7. [Content Brief]
